GSK is planning five phase 3 studies for a gynecologic-cancer antibody-drug conjugate it licensed from Hansoh Pharma after sharing early promising data. The update reflects how ADC developers are scaling confirmatory programs quickly when initial signals support differentiation. While the specific endpoints, trial geography, and patient population details weren’t fully outlined in the brief, the key move is the expansion from early development into a broad phase 3 slate for gynecologic oncology indications. For the industry, the plan underscores continued acceleration of ADC pipeline buildouts in women’s cancers, where combination strategies and antibody targeting have become central to clinical differentiation.